These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32110946)

  • 1. MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma.
    Forschner A; Hilke FJ; Bonzheim I; Gschwind A; Demidov G; Amaral T; Ossowski S; Riess O; Schroeder C; Martus P; Klumpp B; Gonzalez-Menendez I; Garbe C; Niessner H; Sinnberg T
    Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32110946
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Arnoff TE; El-Deiry WS
    Am J Cancer Res; 2022; 12(5):2102-2117. PubMed ID: 35693093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients.
    Hilke FJ; Sinnberg T; Gschwind A; Niessner H; Demidov G; Amaral T; Ossowski S; Bonzheim I; Röcken M; Riess O; Garbe C; Schroeder C; Forschner A
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors.
    Gabryś HS; Basler L; Burgermeister S; Hogan S; Ahmadsei M; Pavic M; Bogowicz M; Vuong D; Tanadini-Lang S; Förster R; Kudura K; Huellner M; Dummer R; Levesque MP; Guckenberger M
    Front Oncol; 2022; 12():977822. PubMed ID: 36505821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.
    Schuiveling M; Tonk EHJ; Verheijden RJ; Suijkerbuijk KPM
    Cancer Immunol Immunother; 2021 May; 70(5):1491-1496. PubMed ID: 32929554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
    Kuk D; Shoushtari AN; Barker CA; Panageas KS; Munhoz RR; Momtaz P; Ariyan CE; Brady MS; Coit DG; Bogatch K; Callahan MK; Wolchok JD; Carvajal RD; Postow MA
    Oncologist; 2016 Jul; 21(7):848-54. PubMed ID: 27286787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Genomic Profiling of Acral Melanoma.
    Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
    J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
    Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham M; Lucas PC; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
    bioRxiv; 2023 Aug; ():. PubMed ID: 37662409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
    Kato S; Goodman A; Walavalkar V; Barkauskas DA; Sharabi A; Kurzrock R
    Clin Cancer Res; 2017 Aug; 23(15):4242-4250. PubMed ID: 28351930
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
    Adashek JJ; Kato S; Ferrara R; Lo Russo G; Kurzrock R
    Oncologist; 2020 Feb; 25(2):94-98. PubMed ID: 32043794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.
    Andrieu C; McNamee N; Larkin AM; Maguire A; Menon R; Mueller-Eisert J; Horgan N; Kennedy S; Gullo G; Crown J; Walsh N
    Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of
    Kato S; Ross JS; Gay L; Dayyani F; Roszik J; Subbiah V; Kurzrock R
    JCO Precis Oncol; 2018; 2018():. PubMed ID: 30148248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
    Jessurun CAC; Vos JAM; Limpens J; Luiten RM
    Front Oncol; 2017; 7():233. PubMed ID: 29034210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
    Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
    Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprogression as a distinct outcome after immunotherapy.
    Fuentes-Antrás J; Provencio M; Díaz-Rubio E
    Cancer Treat Rev; 2018 Nov; 70():16-21. PubMed ID: 30053725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization.
    Glatz-Krieger K; Pache M; Tapia C; Fuchs A; Savic S; Glatz D; Mihatsch M; Meyer P
    Virchows Arch; 2006 Sep; 449(3):328-33. PubMed ID: 16523260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.
    Faure M; Rochigneux P; Olive D; Taix S; Brenot-Rossi I; Gilabert M
    Front Immunol; 2018; 9():797. PubMed ID: 29725330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC).
    Economopoulou P; Anastasiou M; Papaxoinis G; Spathas N; Spathis A; Oikonomopoulos N; Kotsantis I; Tsavaris O; Gkotzamanidou M; Gavrielatou N; Vagia E; Kyrodimos E; Gagari E; Giotakis E; Delides A; Psyrri A
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466719
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperprogression after immunotherapy.
    Abbas W; Rao RR; Popli S
    South Asian J Cancer; 2019; 8(4):244-246. PubMed ID: 31807489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.